Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENGN 
enGene Holdings Inc. Common Stock (ENGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ENGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $21.3
1 Year Target Price $21.3
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.23% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 291.81M USD | Price to earnings Ratio - | 1Y Target Price 21.3 |
Price to earnings Ratio - | 1Y Target Price 21.3 | ||
Volume (30-day avg) 10 | Beta -0.39 | 52 Weeks Range 2.75 - 11.00 | Updated Date 09/15/2025 |
52 Weeks Range 2.75 - 11.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date 2025-09-11 | When After Market | Estimate -0.51 | Actual -0.57 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.67% | Return on Equity (TTM) -43.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 99778697 | Price to Sales(TTM) - |
Enterprise Value 99778697 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 51105200 | Shares Floating 18884132 |
Shares Outstanding 51105200 | Shares Floating 18884132 | ||
Percent Insiders 13.6 | Percent Institutions 89.58 |
Upturn AI SWOT
enGene Holdings Inc. Common Stock
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage genetic medicines company focused on developing gene therapies for various diseases. It was founded with the goal of developing innovative delivery systems for nucleic acid therapeutics.
Core Business Areas
- Gene Therapy Development: Focuses on developing gene therapies for localized cancer and other diseases.
- Proprietary DDX Platform: Utilizes its proprietary, non-viral DDX platform for targeted delivery of therapeutic genes.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its gene therapy candidates.
Leadership and Structure
enGene is led by a management team with experience in biotechnology and gene therapy. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- EG-70 (oncoplasmid for bladder cancer): EG-70 is enGene's lead product candidate, an oncoplasmid designed to deliver IL-12 locally in the bladder for the treatment of non-muscle invasive bladder cancer (NMIBC). Market share data is unavailable as it is still in clinical trials. Competitors include companies developing other therapies for NMIBC such as CG Oncology (CGON) with cretostimogene grenadenorepvec.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing regulatory support for gene therapy products. It includes segments such as cancer, rare diseases, and infectious diseases.
Positioning
enGene is positioned as a player in the localized gene therapy space, focusing on targeted delivery with its DDX platform. Its competitive advantage lies in its non-viral delivery system and its lead product candidate for bladder cancer.
Total Addressable Market (TAM)
The TAM for gene therapies targeting cancer is estimated to be in the billions of dollars. enGene is positioned to capture a share of this market with its localized therapy approach.
Upturn SWOT Analysis
Strengths
- Proprietary DDX platform for gene delivery
- Lead product candidate (EG-70) in clinical development
- Experienced management team
- Potential for targeted and localized gene therapy
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Cash burn rate
- Relatively small market capitalization
Opportunities
- Positive clinical trial results for EG-70
- Partnerships with larger pharmaceutical companies
- Expansion of the DDX platform to other disease areas
- Potential for regulatory approval of gene therapy products
Threats
- Clinical trial failures
- Competition from other gene therapy companies
- Regulatory hurdles
- Financing risks
Competitors and Market Share
Key Competitors
- CGON
- VIRX
Competitive Landscape
enGene competes with other gene therapy companies, particularly those developing therapies for bladder cancer. enGeneu2019s advantage lies in its non-viral DDX delivery system.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, growth is primarily driven by clinical trial progress and pipeline development.
Future Projections: Future growth depends on the success of EG-70 and other pipeline candidates. Analyst estimates require access to financial data platforms.
Recent Initiatives: Recent initiatives include progressing EG-70 through clinical trials and expanding its pipeline with new gene therapy candidates.
Summary
enGene Holdings Inc. is a clinical-stage company with a focus on gene therapy for localized diseases. Its strength lies in its proprietary DDX platform and its lead product candidate, EG-70. The company's main challenges involve successfully navigating clinical trials, securing funding, and competing with larger biotech companies. Its success hinges on positive clinical data and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (General Information)
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial professional. Market share estimates are approximations due to the dynamic nature of the biotechnology industry and the company's clinical stage.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.